Inventor · disambiguated record
Daniel Robert Hostetter
Also filed as: HOSTETTER DANIEL R · HOSTETTER DANIEL ROBERT · Hostetter Daniel
21 granted patents·10 pending applications·165 citations·filing 2013–2023
95Inventor score
Top patents by PatentIndex Score
31 records- 0197US10138272B2Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2016·Granted Nov 27, 2018·31 cites·43 claims
- 0297US9562073B2Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2015·Granted Feb 7, 2017·32 cites·51 claims
- 0396US10669337B2Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the sameCYTOMX THERAPEUTICS INC·Filed 2015·Granted Jun 2, 2020·31 cites·16 claims
- 0495US11028126B2Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2018·Granted Jun 8, 2021·8 cites·54 claims
- 0595US10669339B2Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2019·Granted Jun 2, 2020·10 cites·44 claims
- 0695US9487590B2Activatable antibodies that bind interleukin-6 receptor and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2013·Granted Nov 8, 2016·15 cites·35 claims
- 0794US10336824B2Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of thereofCYTOMX THERAPEUTICS INC·Filed 2016·Granted Jul 2, 2019·16 cites·48 claims
- 0891US11046759B2Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2016·Granted Jun 29, 2021·4 cites·58 claims
- 0990US11161906B2Multispecific antibodies, multispecific activatable antibodies and methods of using the sameCYTOMX THERAPEUTICS INC·Filed 2014·Granted Nov 2, 2021·12 cites·45 claims
- 1086US12459999B2Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2022·Granted Nov 4, 2025·0 cites·8 claims
- 1184US10611845B2Activatable antibodies that bind interleukin-6 receptor and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2016·Granted Apr 7, 2020·2 cites·35 claims
- 1283US2024150402A1Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1382US11802158B2Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the sameCYTOMX THERAPEUTICS INC·Filed 2020·Granted Oct 31, 2023·1 cites·21 claims
- 1482US11174316B2Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2019·Granted Nov 16, 2021·1 cites·19 claims
- 1581US2024150478A1Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1681US2024084022A1Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1779US11548943B2Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2021·Granted Jan 10, 2023·0 cites·9 claims
- 1879US11472875B1Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2021·Granted Oct 18, 2022·0 cites·11 claims
- 1978US11548944B2Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2021·Granted Jan 10, 2023·0 cites·10 claims
- 2077US9255155B2Antibodies specific for urokinase-type plasminogen activator and methods of treating cancerUNIV CALIFORNIA·Filed 2014·Granted Feb 9, 2016·1 cites·52 claims
- 2177US2024084010A1Bispecific anti-cd3 antibodies, bispecific activatable anti-cd3 antibodies, and methods of using the sameCYTOMX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2276US11884746B2Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2021·Granted Jan 30, 2024·0 cites·6 claims
- 2374US2022298245A1Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2473US11814410B2Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2018·Granted Nov 14, 2023·0 cites·28 claims
- 2572US9695249B2Antibodies specific for urokinase-type plasminogen activator and methods of use thereofUNIV CALIFORNIA·Filed 2015·Granted Jul 4, 2017·1 cites·27 claims
- 2664US2020339694A1Activatable antibodies that bind interleukin-6 receptor and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2764US2023331841A1Anti-cd83 car-t cells with regnase-1 and/or tgfbrii disruptionCRISPR THERAPEUTICS AG·Filed 2023·Application pending·0 cites
- 2862US2023128917A1Genetically engineered immune cells having a disrupted cd83 geneCRISPR THERAPEUTICS AG·Filed 2022·Application pending·0 cites
- 2961US2015087810A1Matrix Metalloproteinase Substrates And Other Cleavable Moieties And Methods Of Use ThereofCYTOMX THERAPEUTICS INC·Filed 2014·Application pending·0 cites
- 3061US2021238291A1Multispecific antibodies, multispecific activatable antibodies and methods of using the sameCYTOMX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3160US10239954B2Antibodies specific for urokinase-type plasminogen activator and methods of use thereof for treating cancerUNIV CALIFORNIA·Filed 2017·Granted Mar 26, 2019·0 cites·22 claims
Join the waitlist — get patent alerts
Get an alert when Daniel Robert Hostetter files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →